A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom
- PMID: 24797899
- DOI: 10.1111/ijcp.12451
A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom
Abstract
Aim: To describe and compare adherence and persistence with maintenance therapies in patients with asthma or chronic obstructive pulmonary disease (COPD) in the United Kingdom (UK).
Methods: A retrospective prescribing database cohort was obtained from 44 general practitioner surgeries in National Health Service Forth Valley Scotland. Patients with physician-diagnosed asthma or COPD who received maintenance therapy between January 2008 and December 2009 were included. Five classes of therapy were assessed: inhaled corticosteroids, long-acting beta-agonists, combination therapy inhalers, theophyllines and long-acting muscarinic antagonists. Adherence was calculated using the medication possession ratio (MPR) and persistence was determined using Kaplan-Meier survival analysis for the time to discontinuation (TTD) over 1 year. Two step-wise logistic regressions were performed to assess the contribution of diagnosis to adherence/persistence.
Results: A total of 13,322 patients were included in the analysis: 10,521 patients with asthma and 2801 patients with COPD. 25.2% of medication episodes for asthma and 45.6% of medication episodes for COPD were classified as having an adequate medication supply (MPR of 80-120%). The overall median TTD was 92 days (IQR, interquartile range: 50-186 days) for patients with asthma and 116 days (IQR: 58-259 days, comparison p < 0.001) for patients with COPD. Patients with COPD were found to be more likely to achieve an MPR of at least 80% (OR: 1.27, 95% CI: 1.15-1.40), but had a similar likelihood of persistence at 1 year to patients with asthma.
Conclusion: Adherence and persistence with respiratory therapies in the UK is relatively low. There is suggestion that patients with COPD may display more adherent behaviours than patients with asthma.
© 2014 John Wiley & Sons Ltd.
Similar articles
-
Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset.Respir Med. 2017 Jan;122:1-11. doi: 10.1016/j.rmed.2016.11.008. Epub 2016 Nov 4. Respir Med. 2017. PMID: 27993284
-
Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.COPD. 2014 Sep;11(5):521-30. doi: 10.3109/15412555.2014.922064. Epub 2014 Jun 19. COPD. 2014. PMID: 24945236
-
The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.Int J Chron Obstruct Pulmon Dis. 2015 Oct 29;10:2335-45. doi: 10.2147/COPD.S90155. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26604733 Free PMC article.
-
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.J Allergy Clin Immunol. 2015 Sep;136(3):531-45. doi: 10.1016/j.jaci.2015.05.052. J Allergy Clin Immunol. 2015. PMID: 26343937 Review.
-
Switching treatments in COPD: implications for costs and treatment adherence.Int J Chron Obstruct Pulmon Dis. 2015 Dec 3;10:2601-8. doi: 10.2147/COPD.S79635. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26664108 Free PMC article. Review.
Cited by
-
Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data.BMC Pulm Med. 2022 Oct 18;22(1):383. doi: 10.1186/s12890-022-02167-9. BMC Pulm Med. 2022. PMID: 36258171 Free PMC article.
-
Determining Persistence with an Inhaled Corticosteroid in Asthma: Assessment Using an Objective Measurement vs the Self-Reported Foster Score.J Asthma Allergy. 2022 Jan 5;15:25-33. doi: 10.2147/JAA.S332756. eCollection 2022. J Asthma Allergy. 2022. PMID: 35023932 Free PMC article.
-
The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports.Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231213715. doi: 10.1177/17534666231213715. Ther Adv Respir Dis. 2023. PMID: 38018090 Free PMC article.
-
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD.Int J Chron Obstruct Pulmon Dis. 2020 Nov 26;15:3093-3103. doi: 10.2147/COPD.S263745. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33273812 Free PMC article.
-
Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD.Int J Chron Obstruct Pulmon Dis. 2016 Feb 10;11:289-93. doi: 10.2147/COPD.S96948. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 26929614 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials